Entropy Technologies LP Makes New $557,000 Investment in Harmony Biosciences Holdings, Inc. $HRMY

Posted by George Bondi on Jul 30th, 2026

Entropy Technologies LP purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 19,873 shares of the company’s stock, valued at approximately $557,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Harmony Biosciences by 0.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock worth $1,762,000 after acquiring an additional 298 shares during the period. Nebula Research & Development LLC increased its stake in Harmony Biosciences by 2.0% in the second quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock valued at $550,000 after acquiring an additional 348 shares during the period. The Manufacturers Life Insurance Company increased its stake in Harmony Biosciences by 2.4% in the second quarter. The Manufacturers Life Insurance Company now owns 22,686 shares of the company’s stock valued at $717,000 after acquiring an additional 532 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Harmony Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,799 shares of the company’s stock valued at $105,000 after acquiring an additional 575 shares during the period. Finally, Allworth Financial LP raised its position in Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HRMY shares. Deutsche Bank Aktiengesellschaft raised their price target on shares of Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Tuesday, June 30th. Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Truist Financial increased their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

View Our Latest Stock Analysis on HRMY

Harmony Biosciences Trading Up 0.1%

Shares of Harmony Biosciences stock opened at $35.82 on Thursday. The stock has a market capitalization of $2.07 billion, a P/E ratio of 14.44, a price-to-earnings-growth ratio of 0.33 and a beta of 0.94. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. The company has a 50-day simple moving average of $34.27 and a 200 day simple moving average of $32.56. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21). The firm had revenue of $215.39 million for the quarter, compared to the consensus estimate of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.78 earnings per share. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 3.3 earnings per share for the current fiscal year.

Harmony Biosciences Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.